Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> M Stanley: Proposed US Ban on Use of China Data in Drugmakers' IND Filings; Out-licensing Deals Unaffected
Recommend 6 Positive 8 Negative 6 |
||||
|
||||
|
M Stanley said in a research report that a US congressional appropriations committee has proposed an amendment to prohibit drugmakers from using clinical data from China when submitting Investigational New Drug (IND) applications. IND approval is a prerequisite for drugmakers to commence clinical trials, and China has lower costs, shorter timelines and simpler administrative procedures for IND applications compared with the US. The broker noted that although the bill would face a lengthy process to pass through both the House of Representatives and the Senate, it could in the near term dampen drugmakers willingness to outsource pre-clinical research to China. However, out-licensing activities would not be affected, as in most transactions multinational companies partners typically conduct clinical trials independently in Western countries. (ss/a) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
